The medicine hit its primary endpoint of a decrease in the average daily leg pain intensity as measured by the Numeric Pain ...
Background: Numerical rating scales (NRS), and verbal rating scales (VRS) showed to be reliable and valid tools for subjective cancer pain measurement, but no one of them consistently proved to be ...
Vertex Pharmaceuticals' suzetrigine shows promising results in treating painful lumbosacral radiculopathy, but stock falls ...
A Vertex drug hit its mark in a Phase 2 study in chronic pain, but faces questions about its performance versus placebo.
A single-center retrospective study in China found a significant association between pain duration and intensity in patients ...
Vertex Pharma's non-opioid painkiller suzetrigine was unable to perform better than placebo in a phase 2 trial in lumbar ...
GlobalData on MSN8d
Vertex’s stock hurt after non-opioid pain drug shows benefit similar to placeboVertex said the Phase II trial met its primary endpoint, however there was only a minor difference to placebo.
Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced results from its Phase 2 study of suzetrigine, an ...
Vertex's closely watched drug, suzetrigine, reduced sciatica pain compared to baseline but did not outperform a placebo ...
Vertex Pharmaceuticals’ (NASDAQ:VRTX) investigational non-opioid drug, suzetrigine, has met the primary endpoint in a mid-stage study in people with painful lumbosacral radiculopathy (LSR).
US biopharma Vertex Pharmaceuticals today announced results from its Phase II study of suzetrigine, an investigational, oral, ...
Vertex Pharmaceuticals (NASDAQ: VRTX) fell by 13% on Dec. 19, when the rare-disease drug developer reported some lackluster ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback